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Diabetes is a risk factor for Alzheimer disease (AD). Apolipoprotein E (ApoE) and
several genes related to AD have recently been identified by genome-wide association
studies (GWAS) as being closely linked to lipid metabolism. Lipid metabolism and
glucose-energy metabolism are closely related. Here, we review the emerging evidence
regarding the roles of lipid and glucose metabolism in the modulation of β-amyloid, tau,
and neurodegeneration during the pathogenesis of AD. Disruption of homeostasis of
lipid and glucose metabolism affects production and clearance of β-amyloid and tau
phosphorylation, and induces neurodegeneration. A more integrated understanding of
the interactions among lipid, glucose, and protein metabolism is required to elucidate the
pathogenesis of AD and to develop next-generation therapeutic options.
Keywords: cholesterol, diabetes, Aβ, tau, neurodegeneration
INTRODUCTION
Alzheimer disease (AD) is a progressive neurodegenerative disorder that is pathologically
characterized by cerebral atrophy (particularly within the hippocampus and temporal and parietal
lobes), senile plaques, neurofibrillary tangles (NFT), and neuronal cell death. Familial AD is caused
bymutations in the amyloid precursor protein (Goate et al., 1991) and presenilin (Sherrington et al.,
1995). Thesemutations cause overproduction of β-amyloid (Aβ), particularly its longer form, Aβ42,
which aggregates in vitro (Jarrett et al., 1993) and forms the initial deposits in the brain (Iwatsubo
et al., 1994) to form senile plaques. Apolipoprotein E (ApoE) is an essential regulator of brain
cholesterol metabolism and is the strongest genetic risk factor for sporadic AD (Ashford, 2004).
In addition to the ApoE gene, recent genome-wide association studies (GWAS) have identified
novel risk genes for AD (Hollingworth et al., 2011; Olgiati et al., 2011), and some of these genes
are closely associated with lipid metabolism. Moreover, numerous epidemiological studies have
demonstrated that patients with diabetes in which glucose-energy metabolism is affected have a
significantly higher risk of developing AD (Ott et al., 1999; Kopf and Frölich, 2009; Maher and
Schubert, 2009; Matsuzaki et al., 2010). However, the roles of lipid metabolism and glucose-energy
metabolism in the pathogenesis of AD are not fully understood (Figure 1). Here, we review the
roles of lipid and glucose metabolism in modulating Aβ, tau, and neurodegeneration during the
pathogenesis of AD (Table 1) and focus on novel therapy development.
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FIGURE 1 | The roles of lipid and glucose metabolism in the modulation of β-amyloid and tau during neurodegeneration and the pathogenesis of
Alzheimer disease. Disruption of homeostasis of lipid and glucose metabolism affects production and clearance of β-amyloid and tau phosphorylation, and induces
neurodegeneration.
THE ROLE OF LIPID METABOLISM IN
β-AMYLOID MODULATION
ApoE is an essential regulator of cholesterol metabolism and is
the strongest genetic risk factor for AD (Ashford, 2004). The
ApoEε4 allele increases the accumulation of senile plaques in
patients with AD and in cognitively normal people (Reiman
et al., 2009; Morris et al., 2010). Physiologically, ApoE is
important for brain function through lipid transport of high-
density lipoprotein-like particles (Raber et al., 2000; Ji et al., 2003;
Bu, 2009; Filippini et al., 2009; Trachtenberg et al., 2011; Verghese
et al., 2011; Wisdom et al., 2011). ApoE isoforms are believed to
differentially regulate Aβ aggregation and uptake, degradation,
and phagocytic clearance in the brain, and each isoform has
distinct functions in regulating brain lipid transport, glucose
metabolism, and mitochondrial function (Koistinaho et al., 2004;
Verghese et al., 2013).
Moreover, independently of ApoEε4, high levels of low-
density lipoprotein cholesterol and low levels of high-density
lipoprotein cholesterol are associated with higher amyloid-PET
indices (Reed et al., 2014). This observation may be partially
explained by an in vitro experiment in which transient membrane
cholesterol loading increased Aβ42 secretion (Marquer et al.,
2014). Interestingly, lipids also trigger the aggregation of α-
synuclein, a major component of Lewy bodies, by stimulating
nucleation (Galvagnion et al., 2015). This evidence increases the
possibility that lipids might promote protein aggregation.
In addition to the ApoE gene, recent GWAS studies have
identified novel risk genes for AD (Hollingworth et al., 2011;
Olgiati et al., 2011). These genes include bridging integrator
1 (BIN1), clusterin (CLU, also called apolipoprotein J), ATP-
binding cassette transporter A7 (ABCA7), triggering receptor
expressed onmyeloid cells 2 (TREM2), and phosphatidylinositol-
binding clathrin assembly protein (PICALM). CLU is a primary
brain cholesterol transport lipoprotein and may behave similarly
to ApoE (Calero et al., 1999; Yu and Tan, 2012). ABCA7 is
involved in lipid homeostasis (Tanaka et al., 2011b). Deletion
of ABCA7 increases Aβ accumulation in amyloid precursor
protein transgenic (APP Tg) mice through reduced phagocytic
clearance of Aβ (Kim et al., 2013). TREM2 regulates the
microglial response through lipid sensing around the senile
plaque in an AD mouse model (Wang et al., 2015). BIN1
is involved in endocytosis and membrane trafficking (Itoh
and De Camilli, 2006) through phosphatidylinositol binding
(Lee et al., 2002; Kojima et al., 2004) and also modulates
APP trafficking in neurons (Chapuis et al., 2013). BIN1
expression is also observed in microglia, suggesting a role
for BIN1 in Aβ phagocytosis (Chapuis et al., 2013). PICALM
also plays important roles in clathrin-mediated endocytosis
(Dreyling et al., 1996) through phosphatidylinositol binding
(Ford et al., 2001), suggesting involvement in APP trafficking
(Xiao et al., 2012). Indeed, γ-secretase is endocytosed in a
PICALM-dependent manner (Kanatsu et al., 2014). Interestingly,
altering the rate of clathrin-mediated endocytosis of γ-secretase
increases Aβ42 production (Kanatsu et al., 2014). ApoE also
could modulate γ-secretase cleavage of APP, though all three
isoforms of ε2, ε3, and ε4, have similar effects (Irizarry et al.,
2004). Recent whole-exome sequencing and functional data
indicate that carriers of PLD3 (phospholipase D3) coding
variants have a two-fold increased risk for late-onset AD
and that PLD3 influences APP processing (Cruchaga et al.,
2014).
Although clinical studies have indicated that statins have no
beneficial effect on cognitive function (McGuinness et al., 2014),
statins administered in midlife might prevent AD in late life
by modifying the genetic and non-genetic risk factors for AD
(Sato et al., 2012; Shinohara et al., 2014). In experimental settings
in vivo and in vitro, statins reduced the Aβ level in the brain
Frontiers in Aging Neuroscience | www.frontiersin.org 2 October 2015 | Volume 7 | Article 199
Sato and Morishita Lipid and glucose metabolism in AD










Cholesterol +; Marquer et al.,
2014; Reed et al., 2014
+; Michikawa, 2006; Ohm and
Meske, 2006; Maccioni et al.,
2010; Glöckner and Ohm, 2014;
Shibuya et al., 2015
+; Saher and Stumpf,
2015
APOE +; Irizarry et al., 2004 +; Verghese et al.,
2013
+; Koistinaho et al.,
2004
+; Ohm et al., 1999 +; Belinson et al., 2008
BIN1 +; Itoh and De Camilli,
2006
+; Chapuis et al., 2013 +; Chapuis et al., 2013; Tan
et al., 2013; Holler et al., 2014;
Zhou et al., 2014
CLU +; Yu and Tan, 2012
ABCA7 +; Kim et al., 2013
PICALM +; Kanatsu et al., 2014
TREM2 +; Wang et al., 2015
PLD3 +; Cruchaga et al.,
2014
LRP1 +; Kanekiyo et al.,
2013; Ramanathan
et al., 2015
Statin +; Shinohara et al.,
2010
+; Shinohara et al.,
2010
+; Tanaka et al.,
2011a,b




Diabetes +; Liu et al., 2009; Sato and
Morishita, 2014
+; Sato and Morishita,
2014
Glucose +; Macauley et al.,
2015
+; Sato and Morishita,
2014; Zhu et al., 2014;
Weinstein et al., 2015;
Winkler et al., 2015
Insulin +; Vekrellis et al., 2000;
Shiiki et al., 2004
+; Starks et al., 2015
AMPK +; Mairet-Coello et al., 2013 +; Mairet-Coello et al.,
2013






+; Heneka et al., 2015
Metformin +; Kickstein et al., 2010 +; Moore et al., 2013;
Ng et al., 2014
(Fassbender et al., 2001; Burns et al., 2006; Ostrowski et al., 2007;
Kurinami et al., 2008; Papadopoulos et al., 2014). Aβ reduction
by a statin is associated with a reduction in the carboxyl terminal
fragment of amyloid precursor protein (APP-CTF; Shinohara
et al., 2010). Statins reduce the brain Aβ levels by increasing APP-
CTF trafficking through isoprenylation inhibition. Moreover, a
statin up-regulated Aβ clearance by up-regulating low-density
lipoprotein receptor-related protein 1 (LRP1) expression in the
vasculature (Shinohara et al., 2010). LRP1 play roles in the eﬄux
of Aβ from the brain (Ramanathan et al., 2015) and neuronal
Aβ uptake and degradation (Kanekiyo et al., 2013). Finally,
statins enhance ABCA7-dependent phagocytosis (Tanaka et al.,
2011a). Thus, lipid metabolism is involved in modulating Aβ
levels.
THE ROLE OF LIPID METABOLISM IN TAU
MODULATION
Normal tau promotes the assembly and stabilization of
microtubules. However, hyperphosphorylated tau sequesters
normal tau and disrupts microtubules, forming NFT (Iqbal
et al., 1994, 2009). In mice expressing mutant human tau,
cellular cholesterol levels were higher in neurons affected by
tau pathology (Glöckner and Ohm, 2014). Indeed, impaired
cholesterol metabolism is involved in tau hyperphosphorylation
(Michikawa, 2006; Ohm and Meske, 2006; Maccioni et al., 2010).
Emerging data suggest that BIN1 modulates tau pathology in
addition to Aβ (Chapuis et al., 2013; Tan et al., 2013; Holler et al.,
2014; Zhou et al., 2014). BIN co-localizes and interacts with tau
Frontiers in Aging Neuroscience | www.frontiersin.org 3 October 2015 | Volume 7 | Article 199
Sato and Morishita Lipid and glucose metabolism in AD
(Chapuis et al., 2013; Zhou et al., 2014). Therefore, BIN1 levels
may correlate with NFTs in AD (Glennon et al., 2013; Holler
et al., 2014). In addition to their effects on Aβmetabolism, statins
suppress tau hyperphosphorylation induced by excess cholesterol
in the brain (Lu et al., 2010) and also reduce NFTs in a tau
pathology model (Boimel et al., 2009). Moreover, inhibition of
cholesterol metabolism by blocking acyl-coenzyme A:cholesterol
acyltransferase 1 activity reduces the amount of mutant human
tau in neurons of triple transgenic mice (Shibuya et al., 2015). In
comparison with ApoEε3, the presence of the ApoEε4 is reported
to be associated with NFT formation (Ohm et al., 1999). These
studies demonstrate that the regulation and dysregulation of
cholesterol metabolism affect tau pathology in the brain.
THE ROLE OF LIPID METABOLISM IN
NEURODEGENERATION MODULATION
As the largest pool of cholesterol resides in neuronal myelin
membranes, disorders that impair sterol synthesis or intracellular
trafficking of lipids in neurons cause hypomyelination and
neurodegeneration (Saher and Stumpf, 2015). Glial lipid
droplets induced by mitochondrial defects also promote
neurodegeneration (Liu et al., 2015) suggesting a role for
lipid metabolism in glial cells in neurodegeneration. Moreover,
the human cortex demonstrates membrane protein oxidation
(Granold et al., 2015) and altered phospholipid components
during aging (Norris et al., 2015). Other than AD, impaired
lipid metabolism has been reported in several neurodegenerative
diseases. The huntingtin gene, which is causative for Huntington
disease, also seems to play a regulatory role in lipid metabolism
(Leoni and Caccia, 2015). Cholesterol metabolism impairment
is proportion to the CAG repeat length and to the load of
mutant huntingtin leading to neurodegeneration (Leoni and
Caccia, 2015). Mucopolysaccharidosis III type C, a progressive
neurological pediatric disease, is caused by mutations in the
heparan-α-glucosaminide N-acetyltransferase gene and leads to
a deficiency in acetyl-CoA: α-glucosaminide N-acetyltransferase
(Martins et al., 2015). These results further support the role
of lipid metabolism in neurodegeneration. Although reversible,
statins might transiently impair cognitive function, especially
during the initial administration to patients older than 75 years
(Orsi et al., 2001; King et al., 2003; Wagstaff et al., 2003).
This effect is probably due in part to cholesterol’s modulation
of NMDA receptor function (Korinek et al., 2015). Finally,
activation of Aβ cascade in ApoEε4 transgenic mice induces
lysosomal activation and neurodegeneration resulting in marked
cognitive deficits (Belinson et al., 2008). Taken together, these
reports indicate that cholesterol metabolism is tightly linked to
neurodegeneration.
THE ROLE OF GLUCOSE-ENERGY
METABOLISM IN β-AMYLOID
MODULATION
Diabetes in midlife is associated with mild cognitive impairment
(MCI; Roberts et al., 2014), and impaired glycemia increases the
disease progression to dementia in patients with MCI (Morris
et al., 2014). However, the mechanisms by which diabetes
modifies cognitive function remain unclear (Sato and Morishita,
2013a,b). Diabetes seems to alter brain structure and function
through Aβ/tau-dependent and independent mechanisms (Sato
and Morishita, 2014). Insulin resistance in midlife is associated
with neurodegeneration surrounding senile plaques (Matsuzaki
et al., 2010), though retrospective studies suggest that the
magnitude of senile plaques is comparable between AD with and
without diabetes (Kalaria, 2009). Several groups reported that a
high-fat diet causes Aβ accumulation in the brains of wild type
rabbits (Sparks et al., 1994) and APP Tg mice (Refolo et al.,
2000; Ho et al., 2004). In a murine model of AD, inducing acute
hyperglycemia increases Aβ production (Macauley et al., 2015).
Moreover, altering insulin and insulin signaling may change
Aβ levels in the brain through proteolysis by insulin-degrading
enzymes (Vekrellis et al., 2000) and/or Aβ clearance from the
brain (Shiiki et al., 2004). Alternative mechanisms might include
the accumulation of autophagosomes to enhance amyloidogenic
APP processing (Son et al., 2012) or up-regulation of BACE1
(Guglielmotto et al., 2012). APP+-ob/ob mice, generated by
crossing diabetic ob/ob mice, display increased Aβ deposition in
the cerebral vasculature (Takeda et al., 2010). Whether glycogen
synthase kinase-3(GSK3) controls APP processing and Aβ levels
in brain is intriguing (Phiel et al., 2003; Sereno et al., 2009;
Sofola et al., 2010), but controversial (Jaworski et al., 2011).
Anti-diabetic drug, pioglitazone, stimulated Aβ degradation
by both microglia and astrocytes in ApoE-dependent manner
(Mandrekar-Colucci et al., 2012). Thus, glucose metabolism is
also involved in modulating Aβ levels.
THE ROLE OF GLUCOSE-ENERGY
METABOLISM IN TAU MODULATION
Several neuropathological studies suggest that the magnitude
of NFTs in the brain at autopsy is not different between AD
patients with and without diabetes (Kalaria, 2009). However, one
report suggests that insulin resistance is associated with higher
tau levels in the cerebrospinal fluid (Starks et al., 2015).Moreover,
animal studies show that tau phosphorylation is increased in
diabetes (Clodfelder-Miller et al., 2006; Jolivalt et al., 2008; Ke
et al., 2009; Kim et al., 2009; Qu et al., 2011). For example,
tau phosphorylation is increased in db/db mice (Kim et al.,
2009), streptozotocin-treated wild type mice (Clodfelder-Miller
et al., 2006; Jolivalt et al., 2008; Qu et al., 2011), and mutant
human tau mice (Ke et al., 2009). Importantly, in humans,
tau phosphorylation sites observed in AD are also increased
in the diabetic brain (Liu et al., 2009). Conversely, CSF tau
predicts changes in brain glucose metabolism, in turn causing
longitudinal cognitive changes (Dowling et al., 2015). An energy-
sensor, AMP-activated kinase (AMPK) activation is increased
in the AD brain and AMPK phosphorylates Tau (Mairet-
Coello et al., 2013). GSK3 also induces tau phosphorylation
(Hanger et al., 1992; Yang et al., 1993). Anti-diabetic drug,
metformin induces protein phosphatase 2A activity and reduces
tau phosphorylation in vitro and in animal models (Kickstein
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et al., 2010). Therefore, glucose-energy metabolism is closely
related to modulation of tau.
THE ROLE OF GLUCOSE-ENERGY
METABOLISM IN NEURODEGENERATION
MODULATION
Diabetes causes structural deficits in the brain (Sato and
Morishita, 2014) indicating that glucose-energy metabolism
modulates neurodegeneration. Even in young adults,
hyperglycemia is associated with subtle brain injury and
impaired attention and memory (Weinstein et al., 2015). Indeed,
diabetes reduces the volume of the hippocampus (Moran et al.,
2013; Roberts et al., 2014), gray (García-Casares et al., 2014)
and white matter (Moran et al., 2013). Gray matter loss occurs
in the temporal, anterior cingulate, and frontal lobes (Moran
et al., 2013; García-Casares et al., 2014; Roberts et al., 2014;
Erus et al., 2015), while white matter loss appears in the frontal
and temporal regions (Moran et al., 2013). In patients with AD,
gray matter loss occurs in the temporal lobe, hippocampus,
entorhinal and parietal lobes (Braak and Braak, 1991; Thompson
et al., 2003; Andrade-Moraes et al., 2013), and white matter
loss occurs in the temporal region (Mann, 1991). These studies
indicate that diabetes causes neurodegeneration in the frontal
and temporal lobes and other regions (Sato and Morishita,
2014). The molecular mechanism by which diabetes modulates
neurodegeneration has not been fully elucidated, though several
possible mechanisms have been proposed. Disturbance of glucose
metabolism by GLUT1 deficiency causes neurodegeneration
in APP Tg mice (Winkler et al., 2015). Another link between
glucose hypometabolism and the progression of AD is the
O-GlcNAcylation of proteins (Zhu et al., 2014). Decreased
O-GlcNAcylation occurs in AD, which suggests that glucose
hypometabolismmay impair the protective roles of O-GlcNAc in
neurons and lead to neurodegeneration (Zhu et al., 2014). AMPK
is an energy-sensor, and AMPK over-activation is sufficient to
cause dendritic spine loss (Mairet-Coello et al., 2013). Disturbed
mTOR signaling affected by glucose-energy metabolism also
causes neurodegeneration through mitochondrial dysfunction
and autophagy (Perluigi et al., 2015). An observational study
suggests that pioglitazone treatment is associated with a
reduced dementia risk in diabetes patients (Heneka et al., 2015).
Metformin is also reported to reduce the risk of cognitive decline
in diabetes patients (Ng et al., 2014), though other group showed
an opposite effect (Moore et al., 2013). These studies indicate
that the molecular mechanism by which the dysregulation of
glucose-energy metabolism causes neurodegeneration should be
targeted to develop novel dementia therapies.
SUMMARY
Recent large, long-term, randomized controlled trials suggest
that a multidisciplinary intervention, including exercise and diet,
could improve or maintain cognitive function in at-risk elderly
people (Ngandu et al., 2015). Exercise and diet alter glucose and
lipid metabolism in subjects. As reviewed here, disruption of
homeostasis of lipid and glucose metabolism affects production
and clearance of β-amyloid and tau phosphorylation, and induces
neurodegeneration. Therefore, a more integrated understanding
of the interactions among lipid, glucose, and protein metabolism
will be required to elucidate the pathogenesis of AD and to
develop next-generation therapeutic options.
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